Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Inks Drug Discovery, Development Deal With Chiesi

NEW YORK (GenomeWeb) — Centogene announced on Monday that it has formed a drug discovery and development partnership with Italian drug developer Chiesi.

Under the terms of the deal, Hamburg, Germany-based Centogene will perform a European epidemiological study focused on the prevalence of alpha mannosidosis (AM) — a rare genetic lysosomal storage disorder caused by mutations in the MAN2B1 gene and a core indication for Chiesi. Centogene said it will collect samples from individuals suspected to have AM using its CentoCard dried blood spot collection kit, which it will use to fully sequence MAN2B1 to identify disease-causing mutations.

"Our joint collaboration underpins our globally strong position to speed up the early identification of patients with rare genetic diseases," Centogene CEO Arndt Rolfs said in a statement. "We welcome the opportunity to work with Chiesi … and provide valuable epidemiological and prevalent insights into this devastating condition."

Earlier this year, Centogene — which opened a Boston office in late 2017 — formed a collaboration with Evotec to discover and develop drugs for rare hereditary metabolic diseases and began working with Aldeyra Therapeutics to identify patients with Sjögren-Larsson Syndrome.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.